Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midazolam as second-line treatment for dyspnea in advanced cancer
jRCTs041230106Recruiting
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Dyspnoea (SOB) and cancer comparing Midazolam arm with Placebo arm (2 arms). Primary endpoint: Completion rate (feasibility) at 24 hours. Started Feb 2024; status: recruiting.
02
Drugs
midazolam
03
Conditions
Dyspnoea (SOB)cancer
Beyond the preview
Go deeper on jRCTs041230106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041230106.